Liposome composition

Abstract

To provide a liposome composition which suppresses crystal deposition of ceramides and sterols, has excellent temporal stability in a wide temperature range (crystal suppression effect of ceramides and phytosterols, stability of the liposome composition) and moisture retention effect by moisture occlusion, and is excellent in gloss feeling and tense feeling.SOLUTION: A liposome composition comprising (A) a phospholipid, (B) a phytosterol, (C) a ceramide, and (D) one or more selected from polyhydric alcohols having an IOB value of 1.8 to 3.5 as an ingredient (d1) and / or one or more selected from polyhydric alcohols having an IOB value of 4.5 to 5.5 as an ingredient (d2), wherein a value obtained by weighted-averaging the IOB values of the respective ingredients (D) based on content mass ratios is more than 2.0 and less than 5.0.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a liposome composition. [Background technology]

[0002] It is known that human skin develops various skin problems as it ages, such as dryness and rough skin due to a decrease in the skin's barrier function, and blemishes and sagging due to a decrease in skin elasticity. To date, many products have been developed to resolve aging concerns such as blemishes and sagging by applying technologies that improve barrier function to the skin by applying ceramides and sterols, which are intercellular lipids, to the skin, and by forming a film on the skin to impart luster and firmness.

[0003] Since ceramides and sterols were identified as effective ingredients for improving the skin's barrier function, attempts have been made to develop moisturizing preparations incorporating these active ingredients. However, ceramides and sterols are highly crystalline, and from the viewpoint of improving stability and exerting moisturizing effects on the skin, the development of cosmetics and topical skin preparations that do not cause crystal precipitation has been desired. In particular, it is extremely difficult to stably incorporate them into lotion-based preparations that use water as a medium. Therefore, various studies have been conducted on technologies for stably incorporating these highly crystalline ceramides and sterols into aqueous-based cosmetics.

[0004] To date, a technique has been disclosed in which ceramides and sterols are combined with straight-chain saturated fatty acids to form a liquid crystal composition in order to stably blend ceramides and sterols (see Patent Document 1). Also, as a technique for stabilizing highly crystalline components such as ceramides, a liposome technique has been disclosed in which ceramides are encapsulated in liposomes formed from phospholipids and polyethylene glycol fatty acid esters, resulting in excellent stability in an emulsion composition (see Patent Document 2).

[0005] Furthermore, for skin that has lost elasticity due to aging, a technology has been developed that is highly effective in lifting sagging skin by imparting firmness using oil-soluble and water-soluble film-forming agents. For example, a technology has been disclosed in which an oil-in-water emulsion cosmetic is prepared by blending a highly viscous oil, isotridecyl isononanoate, and polyethylene glycol (see Patent Document 3). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 2020-109074 [Patent Document 2] Japanese Patent Application Laid-Open No. 2011-32229 [Patent Document 3] Japanese Patent Application Laid-Open No. 2007-261971 Summary of the Invention

[0007] However, the liquid crystal composition disclosed in Patent Document 1 contains a straight-chain fatty acid, and therefore, in terms of safety and compatibility with the skin, the moisturizing effect may not be sufficiently exhibited. Furthermore, the liquid crystal composition may have insufficient stability over time at low temperatures, temperature cycles, etc., and may not fully exhibit moisturizing effect and effects such as gloss and firmness.

[0008] In addition, in the technology disclosed in Patent Document 2, although the stability of ceramides is excellent, the moisturizing effect of the ceramides alone may not be sufficient in some cases. Furthermore, the liposome composition may have insufficient stability over time over a wide temperature range, including low temperatures, temperature cycles, and high temperatures, and may not fully exhibit moisturizing effects and effects such as gloss and firmness.

[0009] The technology disclosed in Patent Document 3 improved elasticity by providing firmness, but the inclusion of a water-soluble film-forming agent resulted in stickiness and a glossy feel, which sometimes made usability unsatisfactory.Furthermore, the moisturizing effect was sometimes insufficient.

[0010] As described above, in the prior art, although techniques for suppressing crystallization in compositions and cosmetics containing ceramides and sterols have been disclosed, the moisturizing effect may be insufficient, and it has been difficult to simultaneously achieve effects such as gloss and firmness. Furthermore, the stability over time over a wide temperature range, such as low temperature, temperature cycles, and high temperature, which is assumed to be under various usage environments, may be insufficient. Furthermore, techniques for additionally containing components such as a film-forming agent to enhance gloss and firmness have been reported, but there have been concerns about the destabilization of the liposome composition due to the coexisting components.

[0011] That is, an object of the present invention is to provide a liposome composition that has excellent stability over time, particularly excellent stability over a wide temperature range such as low temperature, temperature cycles, and high temperature (the effect of inhibiting crystal precipitation of ceramides and phytosterols and the stability of the liposome composition), a moisturizing effect due to its moisture-retaining properties, and also excellent gloss and firmness.

[0012] The present inventors have conducted extensive research to solve the above-mentioned problems. As a result, they have found that applying a liposome composition containing ceramides and using phytosterols as a component of the lipid bilayer membrane to the skin not only provides the moisturizing effect of the ceramides, but also forms an occlusive film on the skin, suppressing moisture evaporation and providing a moisturizing effect due to its excellent moisture-occlusive properties. Furthermore, they have found that the liposome composition also provides excellent skin gloss and firmness. However, there are concerns about the dissolution of phytosterols and / or ceramides in coexisting solvents. This leads to instability of the liposome composition due to elution of phytosterols from the liposome composition and precipitation of crystals derived from the phytosterols and / or ceramides, making it extremely difficult to maintain stability over time. However, by adjusting the polarity balance of the polyhydric alcohol contained in the liposome composition within a specific range, it is possible to suppress elution of phytosterols while suppressing crystallization of phytosterols and / or ceramides, and the formation of a liposome composition with excellent stability over time has been confirmed.

[0013] The present inventors have discovered that by combining phospholipids, phytosterols, ceramides, and a polyhydric alcohol with a specific IOB value and adjusting the polarity balance of the polyhydric alcohol within a specific range, not only is stability over time (particularly stability over time over a wide temperature range) achieved, but also excellent usability, such as a moisturizing effect due to excellent moisture-retaining properties, and a glossy, firm feeling, has been achieved, leading to the completion of the present invention.

[0014] That is, the present invention provides the following.

[0015] [1] The following components (A) to (D): (A) Phospholipids (B) Phytosterols (C) Ceramides (D) Component (d1) one or more polyhydric alcohols having an IOB value of 1.8 to 3.5 and / or component (d2) one or more polyhydric alcohols having an IOB value of 4.5 to 5.5 and the IOB value of each component (D) is greater than 2.0 and less than 5.0, calculated as a weighted average based on the mass ratio of the component (D).

[0016] [2] The liposome composition according to [1], wherein the mass ratio of the component (D) to the component (B) [(D) / (B)] is 10 to 60.

[0017] [3] The liposome composition according to [1] or [2], wherein component (D) contains at least component (d1), and the mass ratio of component (d1) to component (B) [(d1) / (B)] is 10 to 40.

[0018] [4] The liposome composition according to any one of [1] to [3], wherein component (d1) is at least one selected from the group consisting of dipropylene glycol, propylene glycol, and 1,3-butylene glycol, and component (d2) is glycerin.

[0019] [5] The liposome composition according to any one of [1] to [4], wherein component (D) contains component (d1) and component (d2), the content of component (d1) is 3 to 20 mass %, the content of component (d2) is 8 to 15 mass %, and the mass ratio of component (d1) to component (d2) [(d1) / (d2)]] is 0.2 to 2.

[0020] [6] The liposome composition according to any one of [1] to [5], wherein the mass ratio of the component (A) to the component (B) [(A) / (B)] is 1 to 30.

[0021] [7] The liposome composition according to any one of [1] to [6], wherein the mass ratio of the content of component (D) to the total amount of component (A) and component (B) [(D) / {(A)+(B)}] is 1 to 20.

[0022] [8] The liposome composition according to any one of [1] to [7] contains liposomes obtained by adding an aqueous component to a mixture obtained by mixing components (A) to (D).

[0023] [9] A cosmetic or external skin preparation containing the liposome composition according to any one of [1] to [8].

[0024]

[10] The cosmetic or topical skin preparation according to [9] further contains component (E') one or more selected from organic acids or inorganic acids and their salts (however, aromatic compounds are excluded as organic acids or inorganic acids).

[0025]

[11] The cosmetic or topical skin preparation according to

[10] , wherein the component (E') is one or more selected from succinic acid and salts thereof.

[0026]

[12] The cosmetic or topical skin preparation according to any one of [9] to

[11] further contains a component (F') hydrolyzed yeast protein.

[0027] Furthermore, the present invention also provides the following aspects.

[0028]

[13] The liposome composition according to any one of [1] to [8], wherein the mass ratio of the component (B) to the component (C) [(B) / (C)] is 1 to 100.

[0029] The liposome composition of the present invention has excellent temporal stability over a wide temperature range (the effect of inhibiting crystal precipitation of ceramides and phytosterols and the stability of the liposome composition), and can provide a moisturizing effect due to its excellent moisture-retaining properties. Furthermore, the liposome composition of the present invention also has excellent gloss and firmness. DETAILED DESCRIPTION OF THE INVENTION

[0030] Hereinafter, embodiments of the present invention will be described. However, the present invention is not limited to the following embodiments. In this specification, the term "X to Y" indicating a range includes X and Y and means "X or more and Y or less."

[0031] In addition, as used herein, the term "liposome composition" refers to a composition containing spherical closed endoplasmic reticulum (liposomes) having a lipid bilayer membrane in an aqueous solvent, and which exhibits a Maltese cross pattern when observed under a polarized microscope. The liposome composition preferably includes liposomes obtained by mixing the components required for liposome formation (components (A) to (D) and an aqueous component). For example, the liposome composition includes liposomes formed by adding an aqueous component to a mixture obtained by mixing components (A) to (D).

[0032] (Component (A): Phospholipid) The phospholipid component (A) used in the present invention is contained as the main component that forms the lipid bilayer membrane of the liposome composition. Such phospholipids are not particularly limited as long as they are those commonly used in cosmetics, quasi-drugs, pharmaceuticals, etc., and examples thereof include soybean-derived phospholipids, soybean-derived hydrogenated phospholipids (hydrogenated soybean phospholipids), soybean-derived lysophospholipids, soybean-derived hydrogenated lysophospholipids, egg yolk-derived phospholipids, egg yolk-derived hydrogenated phospholipids, egg yolk-derived lysophospholipids, and egg yolk-derived hydrogenated lysophospholipids. One or more of these phospholipids can be used as needed. Soybean-derived hydrogenated phospholipids, soybean-derived hydrogenated lysophospholipids, egg yolk-derived hydrogenated phospholipids, and egg yolk-derived hydrogenated lysophospholipids are more preferred, and soybean-derived hydrogenated phospholipids are even more preferred. Soybean-derived hydrogenated phospholipids can be used alone or in combination as needed. In the present invention, the moisturizing effect of the phospholipid itself can be synergistically exerted with the ceramides and phytosterols to impart a moisturizing effect due to water-retaining properties to the liposome composition of the present invention.

[0033] The content of component (A) in the liposome composition of the present invention is not particularly limited, but is preferably 0.5 to 20% by mass (hereinafter simply referred to as "%"), more preferably more than 1% but not more than 20%, even more preferably 1 to 15%, and even more preferably 3 to 10%. This range is preferable because it provides the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, and superior moisture retention (moisture retention), gloss, and firmness. In the present application, the content of a component refers to the total amount when multiple components are included.

[0034] (Component (B): Phytosterol) The component (B) phytosterol used in the present invention is a type of sterol and forms a lipid bilayer membrane together with component (A). Furthermore, when the component (B) phytosterol is combined with component (C) ceramides in the liposome composition, the moisture retention, glossiness, and firmness of the skin are improved. Such phytosterols are found in trace amounts in plants such as soybeans and rapeseed, and are a mixture of multiple sterols, including β-sitosterol, campesterol, stigmasterol, and brassicasterol. In the present invention, component (B) contributes to the stability of the lipid bilayer membrane structure, and its combination can improve the stability of the liposome. Furthermore, because it has a larger molecular weight than other sterols such as cholesterol and is a mixture of multiple sterols, it can impart glossiness and firmness to the liposome composition of the present invention. Furthermore, when combined with ceramides to form a liposome composition containing phytosterol, it forms an occlusive membrane on the skin, suppressing moisture evaporation and providing a moisturizing effect due to its excellent moisture retention. Commercially available phytosterols include Phytosterol QI (manufactured by Eisai Food & Chemical Co., Ltd.). In the present invention, phytosterols can be used in the form of a premix with component (A). Commercially available phospholipid / phytosterol mixtures include PHYTOPRESOME (Nippon Fine Chemical Co., Ltd.). Note that component (B) phytosterols does not include phytosterol derivatives such as polyoxyethylene phytosterols.

[0035] The content of component (B) in the liposome composition of the present invention is preferably 0.05% or more, more preferably 0.1% or more, even more preferably more than 0.1%, and particularly preferably 0.3% or more, from the viewpoints of moisture occlusion, glossiness, and firmness. The content of component (B) in the liposome composition of the present invention is not particularly limited, but is preferably 0.05 to 2%, more preferably 0.1 to 1.5%, even more preferably 0.1 to 1%, even more preferably more than 0.1% but not more than 1%, and particularly preferably 0.2 to 1.0%. This range is more preferable because it provides superior stability, moisture occlusion, glossiness, and firmness of the liposome composition.

[0036] In the present invention, the combination of components (A) and (B) constituting the lipid bilayer membrane of the liposome composition is important. In the present invention, the mass ratio of component (A) to component (B) [(A) / (B)] is not particularly limited, but is preferably 1 to 30, more preferably 1 to 20, even more preferably 2 to 10, even more preferably 2 to 6, particularly preferably more than 2 but not more than 6, and particularly preferably 3 to 6. The mass ratio of component (A) to component (B) [(A) / (B)] refers to the ratio of each component constituting the liposome skeleton. Setting the ratio within this range is more preferable because it provides the stability of the liposome composition, inhibits the crystallization of ceramides and phytosterols, and further improves moisture retention, gloss, and firmness.

[0037] (Component (C): Ceramides) The ceramides (component (C)) used in the present invention are nonionic amphiphiles containing one or more long-chain linear and / or branched alkyl or alkenyl groups, at least two hydroxyl groups, and one or more amide (and / or amino) groups in the molecule, or derivatives in which a phosphatidylcholine residue or a sugar residue is bound to the hydroxyl group of the nonionic amphiphile. These may be natural extracts or synthetic products. Examples include natural ceramides such as sphingosine, phytosphingosine, and their long-chain fatty acid amides (ceramide 1, ceramide 2, ceramide 3, ceramide 4, ceramide 5, and ceramide 6); sphingophospholipids such as sphingomyelin and phytosphingomyelin, which are phospholipid derivatives of sphingosine and phytosphingosine; and glycosphingolipids and phytosphingolipids, such as cerebrosides and gangliosides, which are glycosides of these ceramides. These may be used alone or in combination. Among these, from the viewpoints of moisturizing effect and stability of the liposome composition, natural ceramides are preferred, and ceramide 2 and ceramide 3 are particularly preferred. Commercially available natural ceramides include, for example, Ceramide I, Ceramide III, and Ceramide VI (all manufactured by EVONIC), Ceramide TIC-001 (manufactured by Takasago International Corporation), CERAMIDE 2 (manufactured by Croda Japan), CERAMIDE 3 (manufactured by Cosmopharm), and Ceracare AC45 (manufactured by NFC Corporation).

[0038] The content of component (C) in the liposome composition of the present invention is not particularly limited, but is preferably 0.001 to 2%, more preferably 0.005 to 1%, even more preferably 0.005 to 0.5%, even more preferably more than 0.005% but not more than 0.5%, and particularly preferably 0.01 to 0.5%. This range is more preferable because it provides stability to the liposome composition, inhibits crystallization of ceramides and phytosterols, and provides excellent moisture retention, gloss, and firmness.

[0039] In the liposome composition of the present invention encapsulating ceramides, the combination of components (A) to (C) is important. The mass ratio of the total amount of components (A) and (B) to component (C), [{(A) + (B)} / (C)], is not particularly limited, but is preferably 5 to 1,000, more preferably 10 to 700, and even more preferably 30 to 500, from the viewpoints of stability, moisture retention, glossiness, firmness, etc. of the liposome composition.

[0040] In the liposome composition of the present invention, the combination of component (B) and component (C) is important because it is related to moisture retention, glossiness, firmness, etc. The mass ratio of component (B) to component (C) [(B) / (C)] in the liposome composition is not particularly limited, but is preferably 1 to 200, more preferably 1 to 100, even more preferably more than 1 but not more than 100, and even more preferably 10 to 100. This range is more preferable because it provides the liposome composition with excellent stability, moisture retention, glossiness, and firmness.

[0041] (Component (D): (d1) one or more polyhydric alcohols having an IOB value of 1.8 to 3.5 and / or (d2) one or more polyhydric alcohols having an IOB value of 4.5 to 5.5) The component (D) used in the present invention is a polyhydric alcohol (d1) having an IOB value of 1.8 to 3.5 and / or a polyhydric alcohol (d2) having an IOB value of 4.5 to 5.5. The polyhydric alcohol (d1) having an IOB value of 1.8 to 3.5 and / or the polyhydric alcohol (d2) having an IOB value of 4.5 to 5.5 has a structure containing two or more hydroxyl groups in the molecule. The IOB value in the present invention is a value determined based on the Organic Conceptual Diagram (Fujita, Atsushi, Prediction of Organic Compounds and Organic Conceptual Diagrams, Chemistry Area Vol. 11, No. 10 (1957) 719-715). More specifically, this organic conceptual diagram defines the degree of physical properties of a compound as "organic" and the degree of physical properties as "inorganic," primarily due to van der Waals forces, and "inorganic" respectively. The IOB value is an index showing the balance between inorganic and organic properties, and is expressed as IOB value = inorganic value / organic value. A compound with a higher IOB value is said to have a higher hydrophilic property and polarity. In particular, from the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, the IOB value of component (d1) is preferably 1.8 to 3.3, more preferably 1.8 to 2.5, and the IOB value of component (d2) is preferably 4.5 to 5.0.

[0042] Examples of component (d1) with such an IOB value include dipropylene glycol (IOB value = 1.8), 1,3-butylene glycol (IOB value = 2.5), diglycerin (IOB value = 3.5), and propylene glycol (IOB value = 3.3). From the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, one or more selected from dipropylene glycol, propylene glycol, and 1,3-butylene glycol are preferred, one or two selected from dipropylene glycol and 1,3-butylene glycol are more preferred, and 1,3-butylene glycol is even more preferred. Furthermore, examples of component (d2) include glycerin (IOB value = 5.0) and sorbitol (IOB value = 5.0). From the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, glycerin is preferred. These may be used alone or in combination of two or more.

[0043] The content of component (D) in the liposome composition is not particularly limited, but is preferably 10 to 40%, more preferably 15 to 30%, and even more preferably 20 to 30%. This range is more preferable because it provides better stability of the liposome composition and better effect of inhibiting crystallization of ceramides and phytosterols.

[0044] The content of component (d1) in the liposome composition is not particularly limited, but is preferably 1 to 25%, more preferably 3 to 20%, and even more preferably 6 to 18%. This range is more preferable because it provides better stability of the liposome composition and better effect of inhibiting crystallization of ceramides and phytosterols.

[0045] The content of component (d2) in the liposome composition is not particularly limited, but is preferably in the range of 5 to 20%, more preferably in the range of 8 to 15%, and even more preferably in the range of 8 to 12%, which is more preferable because it provides the liposome composition with a more stable composition and a more effective inhibitory effect on the crystallization of ceramides and phytosterols.

[0046] In one preferred embodiment, from the viewpoint of the temporal stability of the liposome composition over a wide temperature range, component (d1) is at least one selected from the group consisting of dipropylene glycol, propylene glycol, and 1,3-butylene glycol, and component (d2) is glycerin.

[0047] In the present invention, component (D) preferably contains at least component (d1), and more preferably uses components (d1) and (d2) in combination. In the present invention, from the viewpoints of the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, etc., the mass ratio of component (d1) to component (d2) [(d1) / (d2)] is preferably 0.2 to 2, more preferably 0.6 to 1.8, and even more preferably 1 to 1.6.

[0048] In the present invention, component (D) preferably contains at least 1,3-butylene glycol, as this provides good solubility for ceramides and phytosterols, inhibits crystal precipitation, and results in a stable liposome composition. From the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, the mass ratio of 1,3-butylene glycol contained in component (D) [(1,3-butylene glycol) / (D)] is preferably 0.1 to 1, more preferably 0.2 to 0.8, and even more preferably 0.4 to 0.7.

[0049] Furthermore, polyhydric alcohols with low IOB values ​​have excellent affinity for phytosterols, which raises concerns about destabilization of the liposome composition due to phytosterol elution. Therefore, in the liposome composition of the present invention, the polarity balance of component (D) {a value calculated by weighting the IOB values ​​of each component (D) based on the content mass ratio (hereinafter simply referred to as the "weighted average IOB values ​​of component (D)" (hereinafter simply referred to as the "weighted average IOB values ​​of component (D)")} is important. In the present invention, the weighted average IOB value of component (D) is calculated by dividing the sum of the products of the contents (g) of each polyhydric alcohol corresponding to components (d1) and (d2) of component (D) and their IOB values ​​by the sum (g) of the contents of the polyhydric alcohols (a value represented by the following formula (1)). Weighted average of IOB values ​​of component (D) = [(D1: content × IOB value) + (D2: content × IOB value) + (D3: content × IOB value) + ··· / (D1 + D2 + D3 + ···: content)] ··· (Equation 1)

[0050] In the present invention, the weighted average IOB value of component (D) exceeds 2.0 as a lower limit. If the weighted average IOB value of component (D) is 2.0 or less, phytosterols may be eluted over time, resulting in the precipitation of ceramides and phytosterols and the collapse of the liposome composition. Furthermore, the weighted average IOB value of component (D) is less than 5.0 as an upper limit. If the weighted average IOB value of component (D) is 5.0 or more, the phytosterols may not dissolve, resulting in insufficient formation of the liposome composition and a decrease in the stability of the liposome composition. Furthermore, sufficient firmness may not be achieved. The weighted average IOB value of component (D) is preferably 2.3 or more, more preferably 2.5 or more, even more preferably 3.0 or more, even more preferably greater than 3.2, and particularly preferably greater than 3.3. It is preferably 4.6 or less, more preferably 4.0 or less. This range is more preferable because it provides the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, and the moisture-retaining property.

[0051] Furthermore, in the liposome composition of the present invention, it is important to consider the solubility of component (B) relative to component (D). In the present invention, the mass ratio of component (D) to component (B) [(D) / (B)] is not particularly limited, but is preferably 10 or more, more preferably 15 or more, and even more preferably 20 or more. When the mass ratio of component (D) to component (B) [(D) / (B)] is at or above the lower limit, the stability over time (the effect of inhibiting crystallization of ceramides and phytosterols and the stability of the liposome composition) are further improved. The mass ratio of component (D) to component (B) [(D) / (B)] is preferably 300 or less, 250 or less, 100 or less, 60 or less, and 50 or less, in order of preference. Setting it within these ranges is more preferable because it provides superior moisture retention, gloss, and firmness. The mass ratio of component (D) to component (B) [(D) / (B)] is preferably 10 to 250, more preferably 10 to 100, even more preferably 10 to 60, even more preferably 15 to 60, and particularly preferably 15 to 50. Furthermore, the combination with component (d1), which has excellent solubility with component (B), can be appropriately set from the viewpoint of the stability of the liposome composition. In the present invention, the mass ratio of component (d1) to component (B) [(d1) / (B)] is not particularly limited, but is preferably 5 to 150, more preferably 10 to 100, even more preferably 10 to 50, and even more preferably 10 to 40. Setting it within this range is more preferable because it results in superior stability of the liposome composition.

[0052] In the liposome composition of the present invention, the mass ratio of component (D) to the total amount of component (A) and component (B) [(D) / {(A)+(B)}] is not particularly limited, but is preferably in the range of 1 to 20, more preferably in the range of 3 to 17, and even more preferably in the range of 3 to 10. This range is more preferable because it improves the stability of the liposome composition, inhibits the crystallization of ceramides and phytosterols, and provides excellent moisture retention, gloss, and firmness.

[0053] In the liposome composition of the present invention, the ratios of the constituent components (A) to (D) can be appropriately set. In the liposome composition of the present invention, the mass ratio of the total amount of components (A), (B), and (C) to component (D) [{(A) + (B) + (C)} / (D)] is not particularly limited, but is preferably 0.05 to 1, more preferably 0.1 to 0.7, and even more preferably 0.1 to 0.5. This range is preferred because it provides the stability of the liposome composition, inhibits the crystallization of ceramides and phytosterols, and provides excellent moisture retention, gloss, and firmness.

[0054] An aqueous solvent is used as the dispersion medium for the liposome composition of the present invention. The aqueous solvent primarily contains water. Here, "primary component" refers to a solvent containing 50% or more water (up to 100%), preferably 60% or more, more preferably 70% or more, and even more preferably 80% or more water. The water content is not particularly limited, and examples include purified water, hard water, soft water, natural water, tap water, seawater, deep-sea water, electrolytic alkaline ionized water, electrolytic acidic ionized water, ionized water, and cluster water. The water content is not particularly limited, and can be appropriately adjusted depending on the amount of other components. Other aqueous solvents miscible with water may also be used. Examples of other aqueous solvents include lower alcohols such as ethanol and 2-propanol, and these can be used in combination. One or more of these can be mixed together. The liposome composition of the present invention contains (a portion of) component (D) in the aqueous solvent.

[0055] In the present invention, the content of component (D) in the aqueous solvent and the entire component (D) is not particularly limited, but is preferably 10 to 60%, more preferably 20 to 60%, and even more preferably 20 to 50%. This range is more preferable because it improves the stability of the liposome composition, inhibits the crystallization of ceramides and phytosterols, and provides superior moisture occlusion. The content of the aqueous solvent and the entire component (D) in the liposome composition of the present invention is not particularly limited, but is preferably 40 to 99%, and more preferably 50 to 98%.

[0056] The water content in the liposome composition is preferably 20 to 80%, more preferably 30 to 75%, and the water content in the aqueous solvent is preferably 40 to 90%, more preferably 40 to 80%, and even more preferably 50 to 80%. Furthermore, from the viewpoints of the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, and water occlusion properties, the mass ratio of component (D) to water in the liposome composition [component (D) / water] is preferably 0.2 to 2, more preferably 0.2 to 1.5, and even more preferably 0.2 to 1.

[0057] (Component (E): one or more selected from organic acids, inorganic acids, and salts thereof) The liposome composition of the present invention can further contain one or more organic or inorganic acids and their salts as component (E). The use of component (E) prevents crystallization of ceramides and phytosterols and prevents elution of phytosterols, even when stored for a long period of time at high temperatures, resulting in superior stability over time.

[0058] Component (E) used in the present invention is not particularly limited, but examples of organic acids include citric acid, lactic acid, formic acid, acetic acid, oxalic acid, malic acid, tartaric acid, succinic acid, glycolic acid, aspartic acid, glutamic acid, and polyglutamic acid. Examples of inorganic acids include phosphoric acid, hydrochloric acid, sulfuric acid, and boric acid. Examples of salts of organic or inorganic acids include alkali metal salts such as sodium and potassium salts of the above acids, and alkanolamine salts such as triethanolamine salts. Among these, from the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, one or more acids selected from phosphoric acid, citric acid, succinic acid, and salts thereof are more preferred. From the viewpoint of the stability of the liposome composition, one or more acids selected from succinic acid and salts thereof are even more preferred. Specifically, succinic acid and / or sodium succinate are preferred, and a combination of succinic acid and sodium succinate is particularly preferred. Component (E) does not include aromatic compounds such as benzoic acid.

[0059] The content of component (E) in the liposome composition of the present invention is not particularly limited, but is preferably 0.0001 to 1%, more preferably 0.001 to 1%, and even more preferably 0.001 to 0.6%. This range is more preferable because it provides excellent stability of the liposome composition and excellent crystallization-inhibiting effects of ceramides and phytosterols. Furthermore, the mass ratio of component (E) to component (C) [(E) / (C)] is not particularly limited, but is preferably 0.1 to 15, more preferably 0.1 to 12, and even more preferably 0.2 to 5. This range is more preferable because it provides excellent stability of the liposome composition and excellent crystallization-inhibiting effects of ceramides and phytosterols.

[0060] (Component (F): Hydrolyzed yeast protein) The liposome composition of the present invention can be made to have excellent water-retaining properties and / or stability by further using component (F), hydrolyzed yeast protein. In the present invention, hydrolyzed yeast protein refers to proteins obtained by autolysis or acid hydrolysis of yeasts belonging to genus Saccharomyces, Candida, etc., proteins obtained by extracting dried yeast powder with water and glycerin, or water-soluble extracts obtained by placing yeast in a medium and irradiating it with ultraviolet light. While any of the above can be used as the hydrolyzed yeast protein in the present invention, those obtained from yeasts belonging to Candida are preferred. Commercially available products include CHRONOGEN YST (manufactured by ASHLAND).

[0061] The content of component (F) in the liposome composition of the present invention is not particularly limited, but from the viewpoints of the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, and / or the moisture occlusion property, it is preferably 0.0001 to 1%, more preferably 0.0005 to 0.5%, and even more preferably 0.0005 to 0.1%. This range is more preferable because it can impart a moisturizing effect while maintaining the stability of the liposome composition over time.

[0062] In the present invention, the component (E) and / or the component (F) may be contained in the liposome composition, or may be added separately from the composition to prepare a cosmetic or topical skin preparation. However, from the viewpoint of the effects of the present invention (particularly stability over time), it is preferable to add the component (E) and / or the component (F) separately from the liposome composition to prepare a cosmetic or topical skin preparation.

[0063] From the viewpoint of liposome stability, etc., the liposome composition of the present invention preferably has a pH of 5 to 8. By setting the pH in this range, the liposome composition can be made to have excellent stability, moisture retention, and gloss and firmness. In the present application, pH was measured at 20°C using a glass electrode hydrogen ion concentration meter (manufactured by Horiba, Ltd.).

[0064] The liposome composition of the present invention can be produced by conventional methods known to those skilled in the art. While not particularly limited, for example, components (A) to (D) are preheated and mixed uniformly, and then a heated aqueous component is added to the mixture while stirring. The aqueous component essentially contains the aqueous solvent described above and optionally contains other aqueous components. Components (E) and (F) are the aqueous components. The formation of a lipid bilayer membrane can be confirmed by observing the resulting composition under a polarizing microscope under crossed Nicols to determine the presence of a Maltese cross. This can then be subjected to high-pressure treatment, for example, using a high-pressure homogenizer.

[0065] The average particle size of the liposome composition of the present invention is not particularly limited, but from the viewpoint of more suitably exhibiting the effects of the present invention, it is preferably 50 to 300 nm, more preferably 100 to 250 nm, and even more preferably 100 to 200 nm. The average particle size of the liposome composition of the present invention is the value measured in the examples.

[0066] The liposome composition of the present invention may contain optional additives to the extent that they do not impair the effects of the present invention or the formation of the liposome composition. Specific examples of such optional additives include oils, alcohols, powders, water-soluble polymers, film-forming agents, surfactants other than component (A), oil-soluble gelling agents, organically modified clay minerals, resins, UV absorbers, preservatives, antibacterial agents, fragrances, antioxidants, pH adjusters other than component (E), chelating agents, and skin active ingredients.

[0067] In particular, stabilizers such as surfactants, higher alcohols, and higher fatty acids are used in liposome compositions to enhance their stability. While these components can be used in the liposome composition of the present invention, concerns remain regarding safety to the skin, reduced moisture retention, and reduced usability, such as stickiness, due to the stabilizer. Therefore, the content of stabilizers in the liposome composition of the present invention is preferably 1% or less, more preferably 0.5% or less, and even more preferably 0% (none). Examples of stabilizers include surfactants such as anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants other than component (A), higher alcohols such as cetostearyl alcohol and behenyl alcohol, and higher fatty acids such as palmitic acid and stearic acid. Among these, when a stabilizer is used in the present invention, from the viewpoint of the stability and moisture retention of the liposome composition, it is preferable that the stabilizer be a nonionic surfactant, and more preferably a nonionic surfactant having a polyoxyalkylene group.

[0068] Furthermore, in compositions containing ceramides, an oil or the like that dissolves ceramides may be used to inhibit crystal precipitation of ceramides. An oil may also be used in the liposome composition of the present invention. However, since phytosterols that form closed endoplasmic reticulum dissolve (dissolve) in the oil, which may reduce the stability of the liposome composition, cause crystal precipitation, or reduce gloss and firmness due to stickiness, the content of the oil is preferably 1% or less, more preferably 0.5% or less, and even more preferably 0% (none). Here, the oil is not particularly limited as long as it is one that is commonly used in cosmetics, quasi-drugs, pharmaceuticals, etc. Specific examples include vegetable oils such as olive oil, castor oil, mink oil, macadamia nut oil, avocado oil, and medusa oil;Jojoba oil, diisobutyl adipate, 2-hexyldecyl adipate, di-2-heptylundecyl adipate, alkyl glycol monoisostearate, isocetyl isostearate, trimethylolpropane triisostearate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol di-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, pentaerythritol tetra-2-ethylhexanoate, cetyl 2-ethylhexanoate, oleyl oleate, octyldodecyl oleate, decyl oleate Ingredients: dipentaerythritol, neopentyl glycol dicaprate, triethyl citrate, 2-ethylhexyl succinate, isocetyl stearate, butyl stearate, diisopropyl sebacate, di-2-ethylhexyl sebacate, cetyl lactate, myristyl lactate, isopropyl palmitate, 2-ethylhexyl palmitate, 2-hexyldecyl palmitate, 2-heptylundecyl palmitate, dipentaerythritol fatty acid esters, isononyl isononanoate, isotridecyl isononanoate, isopropyl myristate, isopropyl palmitate, myristyl 2-Octyldodecyl Phosphate, 2-Hexyldecyl Myristate, Myristyl Myristate, Hexyldecyl Dimethyloctanoate, Ethyl Laurate, Hexyl Laurate, 2-Ethylhexyl Methoxycinnamate, Diisostearyl Malate, Glyceryl Tri-2-Ethylhexanoate, Glyceryl Caprylate / Caprate, Glyceryl Tricaprate, Glyceryl Triisostearate, Diglyceryl Diisostearate, Diglyceryl Triisostearate, Diglyceryl Tetraisostearate, Decaglyceryl Decaisostearate, Triisostearate Ester oils such as glyceryl palmitate, glyceryl trimyristate, diglyceryl myristate isostearate, tritridecyl trimellitate, N-lauroyl-L-glutamic acid-2-octyldodecyl ester, and N-lauroyl-L-glutamic acid di(phytostearyl·2-octyldodecyl)ester; silicone oils such as low-polymerization dimethylpolysiloxane, high-polymerization dimethylpolysiloxane, methylphenylpolysiloxane, decamethylcyclopentasiloxane, octamethylcyclotetrasiloxane, and fluorine-modified organopolysiloxane;Examples of suitable oil-based additives include fluorine-based oils such as perfluorodecane, perfluorooctane, and perfluoropolyether; hydrocarbons such as isododecane, isohexadecane, light liquid isoparaffin, liquid paraffin, heavy liquid isoparaffin, α-olefin oligomers, squalane, polyisobutylene, and polybutene; lanolin derivatives such as lanolin acetate, lanolin fatty acid isopropyl, and lanolin alcohol; higher alcohols such as isostearyl alcohol and octyldodecanol; higher fatty acids such as isostearic acid and oleic acid; oil-based gelling agents such as dextrin fatty acid esters, sucrose fatty acid esters, starch fatty acid esters, 12-hydroxystearic acid, aluminum stearate, inulin stearate, and calcium stearate; and oil-soluble UV absorbers such as ethyl para-aminobenzoate, 2-ethylhexyl para-methoxycinnamate, 4-tert-butyl-4'-methoxydibenzoylmethane, and oxybenzone.

[0069] The liposome composition of the present invention obtained as described above can be used as a cosmetic or topical skin preparation as is, or can be further combined with other ingredients to form a cosmetic or topical skin preparation. Examples of such cosmetic or topical skin preparations include skin lotions, emulsions, creams, eye creams, serums, massage products, packs, hand creams, body lotions, and other skin care cosmetics; cosmetic bases; and topical skin preparations such as topical liquids, topical gels, creams, ointments, liniments, lotions, poultices, plasters, sprays, and aerosols. The content of the liposome composition in the cosmetic or topical skin preparation is not particularly limited, but is preferably 20 to 80%, more preferably 30 to 70%, and even more preferably 40 to 60% of the cosmetic or topical skin preparation. The formulation is also not particularly limited, and various formulations, such as aqueous cosmetics and oil-in-water cosmetics, are possible. Note that, as used herein, topical skin preparations include quasi-drugs and pharmaceuticals.

[0070] Aqueous cosmetic preparations are a suitable formulation for the cosmetic or topical skin preparation of the present invention. In this specification, "aqueous cosmetic preparations" refers to formulations in which an aqueous phase composed of an aqueous solvent is the continuous phase and which are substantially free of oils. In this specification, "substantially free of oils" means that the content of oils other than components (B) and (C) in the cosmetic preparation is less than 0.5%, preferably less than 0.1%, and more preferably less than 0.05%. Examples of oils include those listed above.

[0071] From the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, it is preferable that the cosmetic contains one or more components selected from component (E') organic acids or inorganic acids and their salts (however, aromatic compounds are excluded as organic acids or inorganic acids), and component (F') hydrolyzed yeast protein. In this specification, to distinguish from components (E) and (F) contained in the liposome composition, one or more components selected from organic acids or inorganic acids and their salts added to cosmetics or topical skin preparations will be referred to as component (E'), and hydrolyzed yeast protein will be referred to as component (F').

[0072] The content of component (E') in the cosmetic or topical skin preparation is not particularly limited, but from the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, the content in the cosmetic or topical skin preparation is preferably 0.0001 to 1%, more preferably 0.001 to 1%, even more preferably 0.001 to 0.6%, even more preferably 0.001% or more but less than 0.6%, and particularly preferably 0.05 to 0.5%. Furthermore, the mass ratio of component (E') to component (C) [(E') / (C)] in the cosmetic or topical skin preparation is not particularly limited, but from the viewpoints of the stability of the liposome composition and the effect of inhibiting crystallization of ceramides and phytosterols, the content is preferably 0.1 to 15%, more preferably 0.1 to 12, and even more preferably 0.2 to 5. Other specific aspects of component (E') are the same as those of component (E) described above for the liposome composition.

[0073] The content of component (F') in the cosmetic or topical skin preparation is not particularly limited, but from the viewpoints of the stability of the liposome composition, the effect of inhibiting crystallization of ceramides and phytosterols, and moisture occlusion, the content in the cosmetic or topical skin preparation is preferably 0.0001 to 1%, more preferably 0.0005 to 0.5%, even more preferably 0.0005 to 0.1%, even more preferably 0.0005% or more but less than 0.1%, and particularly preferably 0.0005 to 0.08%. Other specific aspects of component (F') are the same as those of component (F) described above for the liposome composition.

[0074] Cosmetics or topical skin preparations can contain ingredients typically used in cosmetics or topical skin preparations. Examples of such ingredients include oils, surfactants (anionic surfactants, nonionic surfactants, amphoteric surfactants, cationic surfactants), thickeners (gelling agents, polymers), colorants, powders other than colorants, lower alcohols such as ethanol, polyhydric alcohols, UV absorbers, pH adjusters, antioxidants, metal chelating agents, preservatives, fragrances, and various pharmaceuticals. Cosmetics or topical skin preparations may contain polyhydric alcohols or water, which are the same components as components (A) to (F) and the aqueous component used to form the liposome composition, but these are distinct from components (A) to (F) used in the liposome composition. In other words, if a polyhydric alcohol such as 1,3-butylene glycol is added to a cosmetics or topical skin preparation separately from the liposome composition, the polyhydric alcohol such as 1,3-butylene glycol is distinct from component (D) and is not included in the content of component (D), etc. [Example]

[0075] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to the following examples.

[0076] Liposome composition: Examples 1-1 to 1-14, Comparative Examples 1-1 to 1-4 Liposome compositions were prepared using the following formulation and manufacturing method. Each obtained liposome composition was evaluated for "average particle size," "moisture occlusion," "stability over time (5°C and -10°C ⇔ 20°C / 1 month)," "luster," and "firmness" using the following methods and criteria. The results are shown in Tables 1 and 2.

[0077] [Table 1]

[0078] [Table 2]

[0079] <Manufacturing method> A: Components (1) to (9) were heated to 80°C and mixed uniformly. B: Component (10) was heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: After cooling C to room temperature, it was subjected to high-pressure treatment in a microfluidizer.

[0080] <Evaluation> 1.Average particle size Each sample was filled into a plastic cuvette UVette 220-1600 nm (manufactured by Eppendorf), and the average particle size was measured using a real-time nanoparticle size measurement device DelsaMax CORE (manufactured by Beckman Coulter, Inc.).

[0081] 2. Water occlusion The moisture-retaining property of the present invention was evaluated by the following method in an environment of relative humidity 30 RH% and was judged according to the following three-level judging criteria. A: Put 10g of water into a vial (Vials With Rubber Stopper / V-20, capacity: 20mL). B: The opening of the vial is closed with a filter (GLASS MICROFIBER FILTERS, diameter: 21 mm), and 80 μL of each sample concentrated twice is applied to the top of the filter, and the weight is measured (initial weight). C: After leaving it for 48 hours, measure the weight of the vial (weight after leaving it). D: Calculate the water evaporation rate (%) {[(initial weight - weight after standing) / (initial weight)] x 100}.

[0082] Three-level criteria; [Judgment]: [Judgment criteria] ◎ (Excellent): Water evaporation rate is 1.8% or less ○ (Good): Water evaporation rate is over 1.8% and 2.4% or less × (Not acceptable): Water evaporation rate exceeds 2.4%

[0083] 3. Stability over time (crystallization suppression effect of ceramides and phytosterols) After storage for one month at constant temperatures of 5°C and -10°C to 20°C (24-hour cycle), the liposome compositions were observed under polarized light using an upright microscope (Olympus) at a magnification of 400x and an exposure time of 1 / 200 seconds. Under polarized light, ceramides and phytosterols present as crystals in the composition are observed as white glittering matter. Even if crystal glittering matter is not present, if crystallization has progressed, the composition is observed under the microscope as a grayish image of unclear ceramides and phytosterol glittering matter. The effect of inhibiting ceramide and phytosterol crystallization was evaluated by observing the presence or absence of ceramide and phytosterol-derived crystals and rating the composition according to the following three-level evaluation criteria.

[0084] Three-level criteria; [Judgment]: [Judgment criteria] ◎ (Excellent): No crystalline glitter derived from ceramides or phytosterols is observed ○ (Good): Unclear crystalline glitter derived from ceramides and / or phytosterols is observed × (Fail): Crystalline glitter derived from ceramides and phytosterols is observed

[0085] 4. Stability over time (stability of liposome composition) The average particle size of each sample after storage at constant temperatures of 5°C and -10°C to 20°C for one month was measured using the evaluation method described above. The retention of the liposome composition formation was evaluated from the rate of change in the average particle size relative to the value immediately after production, and the stability of the liposome composition was assessed using the following four-level evaluation criteria.

[0086] 4-level criteria; [Judgment]: [Judgment criteria] ◎ (Excellent): The rate of change in average particle size is less than ±20% ○ (Good): The rate of change in average particle size is between ±20% and ±40% △ (slightly unacceptable): The rate of change in average particle size is between ±40% and ±60% × (Not acceptable): The rate of change in average particle size is ±60% or more

[0087] 5. Shiny and firm Ten cosmetic expert evaluation panel members aged 35 to 50 years old were asked to take a rice-sized amount of each of the samples of the present invention products 1-1 to 1-14 and the comparative products 1-1 to 1-4 in their hands and apply it to their entire faces after washing their faces twice a day, morning and evening. This was done for two weeks, and the gloss and firmness of each sample were evaluated sensorily on a five-point scale according to the following (1) evaluation criteria, and the average score of each sample was further evaluated according to the following (2) four-point evaluation criteria.

[0088] (1) Evaluation criteria; [Evaluation result]: [Score] Very good: 5 points Good: 4 points Average: 3 points Slightly poor: 2 points Defective: 1 point (2) Judgment criteria; [Judgment]: [Average score] ◎ (Excellent): 4.5 or above ○ (Good): 3.5 or more and less than 4.5 △ (slightly unacceptable): 1.5 or more and less than 3.5 × (unacceptable): Less than 1.5.

[0089] As is clear from Tables 1 and 2, all of the liposome compositions of Examples 1-1 to 1-14 were found to have excellent stability and excellent effects of inhibiting crystallization of ceramides and phytosterols, and were also found to have excellent effects such as moisture retention and gloss and firmness.

[0090] On the other hand, as shown in Table 2, Comparative Example 1-1, which did not contain phytosterol, was unsatisfactory in terms of moisture occlusion, stability over time of the liposome composition, and gloss and firmness. Comparative Example 1-2, in which cholesterol was used instead of phytosterol, was excellent in liposome stability, but was insufficient in gloss and firmness. Furthermore, in Comparative Example 3, in which the weighted average IOB value of component (D) was 2.0, crystals derived from ceramides and phytosterol were observed, confirming destabilization of the liposome composition. Comparative Example 4, in which the weighted average IOB value of component (D) was 5.0, was unsatisfactory in terms of stability and firmness of the liposome composition. The liposome compositions obtained in the examples all had a pH of 5 to 8.

[0091] Preparation of aqueous cosmetics: Examples 2-1 to 2-9 Aqueous cosmetics containing liposome compositions were prepared according to the following formulation and manufacturing method, and their "stability over time (50°C / 1 month)" was evaluated using the same methods and criteria as above. The results are shown in Table 3.

[0092] [Table 3]

[0093] <Manufacturing method> A: Components (1) to (6) were heated to 80°C and mixed uniformly. B: Component (7) was heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: After cooling C to room temperature, it was subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (8) to (15) were mixed uniformly. F: D was added to E and mixed to prepare a cosmetic.

[0094] <Evaluation> 5. Stability over time (crystallization suppression effect of ceramides and phytosterols) After storing each sample at a constant temperature of 50°C for one month, it was evaluated according to the above methods and criteria. 6. Stability over time (stability of liposome composition) After storing each sample at a constant temperature of 50°C for one month, it was evaluated according to the above methods and criteria.

[0095] As is clear from Table 3, the aqueous cosmetics of Examples 2-1 to 2-9 all had excellent stability of the liposome composition even at high temperatures, and also had excellent effects of inhibiting crystallization of ceramides and phytosterols. Furthermore, Examples 2-1 to 2-9 also had excellent effects such as stability over time at low temperatures and at temperature cycles, moisture retention, and gloss and firmness. The obtained liposome compositions all had a pH of 5 to 8.

[0096] Example 2-10: Cloudy lotion containing liposome composition (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 5.5 (2) Phytosterol Note 1 (ingredient (B)) 1.0 (3) Ceramide 2 Note 2 (ingredient (C)) 0.02 (4) Glycerin (ingredient (D)) 10 (5) 1,3-butylene glycol (ingredient (D)) 15 (6) Succinic acid (component (E)) 0.0007 (7) Disodium succinate (component (E)) 0.0033 (8) Hydrolyzed Yeast Protein Note 4 (Component (F)) 0.001 (9) Water remaining (68.475) (liposome composition 50%) (10) Hydrolyzed hyaluronic acid 1.0 (11) Tocopherol 0.05 (12) (Acrylates / acrylic acid (C10-30) crosspolymer) 0.4 (13) Dipropylene glycol 3.0 (14) Sodium hydroxide 0.15 (15) Phenoxyethanol 0.5 (16) Sodium benzoate 0.001 (17) Water remaining (44.899) (Liposome composition: 100% of components (1) to (9), lotion: 50% of liposome composition of components (1) to (9), 50% of post-additives of components (10) to (17), total 100%; the same applies to the following examples.) (Manufacturing method) A: Components (1) to (3) and (5) were heated to 80°C and mixed uniformly. B: Component (4) heated to 80°C was added to A and mixed uniformly. C: Components (6) to (9) heated to 80°C were gradually added to B and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high-pressure treatment in a microfluidizer to obtain a liposome composition. The stability of the liposome composition at 50°C and 1M (prevention of crystallization of ceramides and phytosterols and retention of liposome composition formation) was rated as ⊚ according to the above evaluation criteria. E: Components (10) to (17) were mixed with D to obtain a cloudy lotion.

[0097] The resulting opaque lotion exhibited excellent stability of the liposome composition, with no crystalline precipitation of ceramides or phytosterols. Furthermore, it also exhibited excellent moisture retention and effects such as gloss and firmness. The weighted average IOB value of the contained component (D) was 3.5. Furthermore, [(A) / (B)] = 5.5, [(D) / (B)] = 25, and [(D) / {(A)+(B)}] = 3.8.

[0098] Example 2-11: Cloudy lotion containing liposome composition (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 8.0 (2) Phytosterol Note 1 (ingredient (B)) 2.0 (3) Ceramide 2 Note 2 (ingredient (C)) 0.02 (4) Glycerin (ingredient (D)) 11 (5) 1,3-butylene glycol (ingredient (D)) 10 (6) Dipropylene glycol (ingredient (D)) 4.0 (7) Succinic acid (component (E)) 0.01 (8) Disodium succinate (ingredient (E)) 0.05 (9) Hydrolyzed Yeast Protein Note 4 (Component (F)) 0.01 (10) Water remaining (liposome composition 60%) (11) Xanthan gum 0.1 (12) Tocopherol 0.05 (13) Carbomer 0.4 (14) Hydroxyethyl cellulose 0.2 (15) Sodium hydroxide 0.15 (16) Phenoxyethanol 0.5 (17) Ethanol 1.0 (18) Sodium benzoate 0.001 (19) Water remaining (Manufacturing method) A: Components (1) to (6) were heated to 80°C and mixed uniformly. B: Components (7) to (10) were heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (11) to (19) were mixed with D to obtain a cloudy lotion.

[0099] The resulting opaque lotion exhibited excellent stability of the liposome composition, with no crystalline precipitation of ceramides or phytosterols. Furthermore, it also exhibited excellent moisture retention and effects such as gloss and firmness. The weighted average IOB value of the contained component (D) was 3.5. Furthermore, [(A) / (B)] = 4, [(D) / (B)] = 12.5, and [(D) / {(A)+(B)}] = 2.5.

[0100] Example 2-12: Liposome composition-containing cosmetic serum (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 3.0 (2) Phytosterol Note 1 (ingredient (B)) 0.5 (3) Ceramide 2 Note 2 (ingredient (C)) 0.05 (4) Glycerin (ingredient (D)) 10 (5) 1,3-butylene glycol (ingredient (D)) 15 (6) Water remaining (liposome composition 50%) (7) Xanthan gum 0.3 (8) Carbomer 0.3 (9) Hydroxyproline 0.1 (10) Tocopherol 0.02 (11) Succinic acid (component (E')) 0.01 (12) Disodium succinate (component (E')) 0.05 (13) Hydrolyzed yeast protein Note 4 (component (F')) 0.05 (14) Sodium benzoate 0.001 (15) Sodium hydroxide 0.1 (16) Water remaining (Manufacturing method) A: Components (1) to (3) and (5) were heated to 80°C and mixed uniformly. B: Component (4) heated to 80°C was added to A and mixed uniformly. C: Component (6) heated to 80°C was gradually added to B and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (7) to (16) were mixed uniformly. F: D was added to E and mixed uniformly to obtain a beauty serum.

[0101] The resulting serum exhibited excellent stability of the liposome composition, with no precipitation of ceramide or phytosterol crystals. Furthermore, it also exhibited excellent moisture retention and effects such as gloss and firmness. The weighted average IOB value of the contained component (D) was 3.5. Furthermore, [(A) / (B)] = 6, [(D) / (B)] = 50, and [(D) / {(A)+(B)}] = 7.1.

[0102] <Example 2-13 Oil-in-water emulsion containing liposome composition> (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 3.0 (2) Phytosterol Note 1 (ingredient (B)) 0.5 (3) Ceramide 2 Note 2 (ingredient (C)) 0.05 (4) Glycerin (ingredient (D)) 10 (5) 1,3-butylene glycol (ingredient (D)) 15 (6) Dipropylene glycol (ingredient (D)) 5.0 (7) Water remaining (liposome composition 50%) (8) Hydrogenated polydecene Note 5 0.5 (9) Macadamia nut fatty acid phytosteryl Note 6 0.5 (10) Tocopherol 0.01 (11) Cetyl 2-ethylhexanoate 1.0 (12) Polyoxyethylene hydrogenated (60) castor oil 0.8 (13) Cetostearyl alcohol 0.15 (14) (Acrylates / acrylic acid (C10-30) crosspolymer) 0.2 (15) Carbomer 0.3 (16) Xanthan gum 0.1 (17) Sodium hydroxide 0.15 (18) Succinic acid (component (E')) 0.01 (19) Disodium succinate (component (E')) 0.05 (20) Hydrolyzed yeast protein Note 4 (component (F')) 0.5 (21) Sodium benzoate 0.015 (22)Fragrance 0.1 (23) Ethanol 2.0 (24)EDTA-2Na 0.05 (25) Phenoxyethanol 0.5 (26) Water remaining Note 5: SILKFLO 364 (manufactured by LIPO CHEMICALS INC.) Note 6: PLANDOOL-MAS (manufactured by Nippon Fine Chemicals Co., Ltd.) (Manufacturing method) A: Components (1) to (6) were heated to 80°C and mixed uniformly. B: Component (7) was heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (8) to (13) were heated to 70°C and mixed uniformly. F: Components (24), (25) and a portion of (26) were heated to 70°C and mixed uniformly. G: F was added to E, and emulsified by stirring using a Despa mixer. H: After G was cooled to room temperature, D, components (14) to (23) and the remainder of (26) were added and mixed uniformly to obtain an oil-in-water emulsion.

[0103] The resulting oil-in-water emulsion exhibited excellent stability of the liposome composition, with no crystalline precipitation of ceramides or phytosterols. Furthermore, it also exhibited excellent moisture retention and effects such as gloss and firmness. The weighted average IOB value of the contained component (D) was 3.2. Furthermore, [(A) / (B)] = 6, [(D) / (B)] = 60, and [(D) / {(A)+(B)}] = 8.6.

[0104] <Example 2-14: Oil-in-water cream containing liposome composition> (Formulation) [mass%] (1) Phospholipid (Component (A)) 3.0 (2) Phytosterol Note 1 (ingredient (B)) 0.5 (3) Ceramide 2 Note 2 (ingredient (C)) 0.05 (4) Glycerin (ingredient (D)) 12 (5) 1,3-butylene glycol (ingredient (D)) 10 (6) Dipropylene glycol (ingredient (D)) 2.0 (7) Water remaining (liposome composition 40%) (8) Hydrogenated isobutene Note 7 3.0 (9) Di(octyldodecyl / phytosteryl / behenyl) lauroyl glutamate Note 8 0.4 (10) Tocopherol 0.02 (11) Triethylhexanoin 2.0 (12) Lauryl Polyglyceryl-3 Polydimethylsiloxyethyl Dimethicone Note 9 0.1 (13) Cetostearyl alcohol 0.8 (14) (Acrylates / acrylic acid (C10-30) crosspolymer) 0.2 (15) Carbomer 0.2 (16) Xanthan gum 0.1 (17) Hydroxypropylmethylcellulose 0.01 (18) Sodium hydroxide 0.15 (19) Succinic acid (component (E')) 0.03 (20) Disodium succinate (component (E')) 0.15 (21) Sodium monohydrogen phosphate (component (E')) 0.03 (22) Sodium dihydrogen phosphate (component (E')) 0.3 (23) Hydrolyzed yeast protein Note 4 (component (F')) 0.1 (24) Sodium benzoate 0.003 (25)Fragrance 0.2 (26) Ethanol 3.0 (27)EDTA-2Na 0.05 (28) Phenoxyethanol 0.5 (29) Water remaining Note 7: Pearleem 18 (NOF Corporation) Note 8: Eldew PS-306 (Ajinomoto Co., Inc.) Note 9: KF-6105 (Shin-Etsu Chemical Co., Ltd.) (Manufacturing method) A: Components (1) to (6) were heated to 80°C and mixed uniformly. B: Component (7) was heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (8) to (13) were heated to 70°C and mixed uniformly. F: Components (27), (28) and a portion of (29) were heated to 70°C and mixed uniformly. G: F was added to E, and emulsified by stirring using a Despa mixer. H: After G was cooled to room temperature, D and the rest of the components (14) to (26) and (29) were added and mixed uniformly to obtain an oil-in-water cream.

[0105] The resulting oil-in-water cream exhibited excellent stability of the liposome composition, and no crystalline precipitation of ceramides or phytosterols was observed. Furthermore, it also exhibited excellent moisture retention and effects such as gloss and firmness. The weighted average IOB value of the contained component (D) was 3.7. Furthermore, [(A) / (B)] = 6, [(D) / (B)] = 48, and [(D) / {(A)+(B)}] = 6.9.

[0106] Example 2-15: Oil-in-water cream containing liposome composition (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 3.0 (2) Phytosterol Note 1 (ingredient (B)) 0.5 (3) Ceramide 2 Note 2 (ingredient (C)) 0.05 (4) Glycerin (ingredient (D)) 6.0 (5) 1,3-butylene glycol (ingredient (D)) 6.0 (6) Water remaining (liposome composition 40%) (7) Hydrogenated soybean phospholipid 2.5 (8) Glycerin 10 (9) 1,3-butylene glycol 3.0 (10) Di(octyldodecyl / phytosteryl / behenyl) lauroyl glutamate Note 8 1.0 (11) Phytosteryl Oleate 0.5 (12) Diphenylsiloxyphenyl Trimethicone 1.0 (13) Dimethicone (100cs) 1.0 (14) Cetostearyl alcohol 0.8 (15) (Acrylates / acrylic acid (C10-30) crosspolymer) 0.2 (16) Xanthan gum 0.1 (17) Hydroxypropyl methylcellulose 0.01 (18) Sodium hydroxide 0.15 (19) Water remaining (20) Methylgluceth-10 3.0 (21)EDTA-2Na 0.05 (22) Phenoxyethanol 0.5 (23)Fragrance 0.2 (Manufacturing method) A: Components (1) to (5) were heated to 80°C and mixed uniformly. B: Component (6) was heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (7) to (14) were heated to 70°C and mixed uniformly. F: Components (15) to (21) were heated to 70°C and mixed uniformly. G: F was added to E, and emulsified by stirring using a Despa mixer. H: After G was cooled to room temperature, D, components (22) and (23) were added and mixed uniformly to obtain an oil-in-water cream.

[0107] The resulting oil-in-water cream exhibited excellent stability of the liposome composition, and no crystalline precipitation of ceramides or phytosterols was observed. Furthermore, it also exhibited excellent moisture retention, gloss, firmness, and richness during use. The weighted average IOB value of the contained component (D) was 3.8. Furthermore, [(A) / (B)] = 6, [(D) / (B)] = 24, and [(D) / {(A)+(B)}] = 3.4.

[0108] Example 2-16: Cosmetic serum containing liposome composition (Formulation) [mass%] (1) Hydrogenated soybean phospholipid (ingredient (A)) 3.0 (2) Phytosterol Note 1 (ingredient (B)) 0.5 (3) Ceramide 2 (ingredient (C)) 0.01 (4) Glycerin (ingredient (D)) 5.0 (5) 1,3-butylene glycol (ingredient (D)) 7.5 (6) Succinic acid (ingredient (E)) 0.01 (7) Disodium succinate (component (E)) 0.05 (8) Remaining purified water (liposome composition 60%) (9) Hydrogenated soybean phospholipid 4.5 (10)POE(30)Phytosterol 3.0 (11) Dipropylene glycol 20 (12) EDTA-2Na 0.05 (13) Remaining purified water (Bicell composition 10%) (14) Carrageenan Note 10 0.1 (15) Remaining purified water (16) Ethanol 4.0 Note 10: Carrageenan J (Kyokuto Chemical Industry Co., Ltd.) (Manufacturing method) A: Components (1) to (5) were heated to 80°C and mixed uniformly. B: Components (6) to (8) were heated to 80°C. C: B was gradually added to A and dispersed using a Despa mixer. D: C was cooled to room temperature and subjected to high pressure treatment in a microfluidizer to obtain a liposome composition. E: Components (9) to (11) were heated to 80°C and mixed uniformly. F: Components (12) and (13) were heated to 80°C and mixed uniformly. G: F was added to E and stirred with a Despa mixer to obtain a bicelle structure dispersion. H: After G was cooled to room temperature, D and previously mixed and dissolved components (14), (15) and (16) were added and mixed uniformly to obtain a beauty serum.

[0109] The resulting serum exhibited excellent stability of the liposome composition, with no crystalline precipitation of ceramides or phytosterols. Furthermore, it also exhibited excellent moisture retention, radiance, firmness, and richness during use. The weighted average IOB value of the contained component (D) was 3.5. Furthermore, [(A) / (B)] = 6, [(D) / (B)] = 25, and [(D) / {(A)+(B)}] = 3.6.

[0110] This application is based on Japanese Patent Application No. 2021-31283, filed on February 27, 2021, the disclosure of which is incorporated by reference in its entirety.

Claims

1. The following components (A) to (D): (A) Phospholipids (B) Phytosterol (C) Ceramides (D) Component (d1) one or more polyhydric alcohols having an IOB value of 1.8 to 3.5 and / or component (d2) one or more polyhydric alcohols having an IOB value of 4.5 to 5.5 wherein the IOB value of each of the components (D) is greater than 2.0 and less than 5.0, as calculated by weighted average based on the content mass ratio of each component (D).

2. 2. The liposome composition according to claim 1, wherein the mass ratio of the component (D) to the component (B) [(D) / (B)] is 10 or more.

3. 3. The liposome composition according to claim 1, wherein the component (D) contains at least the component (d1), and the mass ratio of the component (d1) to the component (B) [(d1) / (B)] is 10 to 40.

4. The liposome composition according to any one of claims 1 to 3, wherein the component (d1) is at least one selected from the group consisting of dipropylene glycol, propylene glycol, and 1,3-butylene glycol, and the component (d2) is glycerin.

5. 5. The liposome composition according to claim 1, wherein the component (D) contains the component (d1) and the component (d2), the content of the component (d1) is 3 to 20% by mass, the content of the component (d2) is 8 to 15% by mass, and the content mass ratio of the component (d1) to the component (d2), [(d1) / (d2)], is 0.2 to 2.

6. 6. The liposome composition according to claim 1, wherein the mass ratio of the component (A) to the component (B) [(A) / (B)] is 1 to 30.

7. 7. The liposome composition according to claim 1, wherein the mass ratio of the content of the component (D) to the total amount of the component (A) and the component (B), [(D) / {(A)+(B)}], is 1 to 20.

8. The liposome composition according to any one of claims 1 to 7, comprising liposomes obtained by adding an aqueous component to a mixture obtained by mixing the components (A) to (D).

9. A cosmetic or external skin preparation comprising the liposome composition according to any one of claims 1 to 8.

10. The cosmetic or topical skin preparation according to claim 9, containing component (E') one or more selected from organic acids or inorganic acids and their salts (however, aromatic compounds are excluded as organic acids or inorganic acids).

11. The cosmetic or topical skin preparation according to claim 10, wherein the component (E') is one or more selected from succinic acid and salts thereof.

12. The cosmetic or topical skin preparation according to any one of claims 9 to 11, which contains component (F') hydrolyzed yeast protein.

Images